Shares of molecular diagnostics firm Genetic Technologies Limited (GENE) are up $1.16, or 28%, at $5.38, in early trading, after the company this morning announced that a further two new breast health centers will begin to offer BREVAGenplus to their at-risk patients in a systematic fashion. Genetic Tech said that this is in addition to […]
View the full post at: Genetic Tech (GENE) Surges 28% As Additional Breast Health Centres Begin Offering BREVAGenplus